Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Condition: Myasthenia Gravis Interventions: Drug: HBM9161 Injection (680mg); Drug: HBM9161 Drug Product (340mg) Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Myasthenia Gravis | Research